The world has just recovered from a pandemic that claimed crores of lives across the globe. This was the first time that our ...

Biosciences presented subgroup analyses and data from the KINECT-HD study showing the impact of Iingrezza – valbenazine ...

The findings revealed that the consistent efficacy of Ingrezza in reducing chorea across various subgroups and its potential positive impact on emotional health in patients. Currently, Neurocrine's ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

(Asian Journal of Psychiatry) In April, the FDA approved a new oral granule formulation of the vesicular monoamine ...

Few people would likely disagree that, once we learn how, genetically preventing tragic diseases such as Huntington's chorea would be acceptable, if not prescribed. NOVA: Is it ethical to alter ...

The birth of Dolly, the first mammal cloned from the cell of an adult animal, sent intellectual and emotional shockwaves around the world when it was reported in early 1997. What's next ...

Principal Financial Group Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

The fellows gain expertise in diagnosing and treating Parkinson’s disease, atypical Parkinsonian syndromes, dystonia, tremor, Huntington’s disease, chorea, myoclonus, ballism, Tourette syndrome, tics, ...

Q3 2024 Earnings Call Transcript October 30, 2024 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...